Rick Klaus­ner fronts cash for his fun­gus out­fit LifeM­ine and brings on No­bel lau­re­ate to fur­ther push can­cer dis­cov­ery

More than three years af­ter launch­ing with a $55 mil­lion Se­ries A, fun­gus play­er LifeM­ine Ther­a­peu­tics is back with a tri­fec­ta of new good­ies: cash, a promi­nent in­vestor and a No­bel lau­re­ate.

Rick Klaus­ner is lead­ing a $50 mil­lion Se­ries B round with his Milky Way In­vest­ments for LifeM­ine, which he al­so co-found­ed, as it aims to ex­pand its ef­forts in bring­ing fun­gi to the fore­front of drug R&D, the com­pa­ny said Thurs­day. William Kaelin, who won the 2019 No­bel Prize in Phys­i­ol­o­gy or Med­i­cine for his work in un­der­stand­ing how cells sense and adapt to changes in oxy­gen, is al­so join­ing LifeM­ine’s board of di­rec­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER